Another Day, Another Biotech Ripping Before The Bell

By: Dylan Sikes – AllPennyStocks.com News

Thursday, March 20, 2025

A Pennsylvania-based biotech firm is already off to the races during Thursday’s premarket hours after the company announced that it has entered into a license and supply agreement to become a sourcing partner for Evofem Biosciences for Evofem’s PHEXXI.

Traders rushed to buy up shares of Windtree Therapeutics Inc. (Nasdaq:WINT), with the micro cap currently being bid up at $2.57/share (+52.07% implied open for sellers) at the time of writing. This move will be the first signs of life for this stock as it has been crushed by selling pressure since the start of the year.

Windtree Therapeutics Inc is a development-stage biotechnology company focused on developing KL4 surfactant therapies for respiratory diseases. Its technology platform includes synthetic, peptide-containing surfactant and novel drug delivery technologies that deliver aerosolized KL4 surfactants without invasive procedures. Its development program utilizing its proprietary technology platform is AEROSURF which is being developed for the treatment of respiratory distress syndrome in premature infants. It operates in the business segment of research and development of products focused on surfactant therapies for respiratory disorders and diseases, and the manufacture and commercial sales of approved products.

Copyright © 2025 AllPennyStocks.com. All rights reserved. Republication or redistribution of AllPennyStocks.com's content is expressly prohibited without the prior written consent of AllPennyStocks.com. AllPennyStocks.com shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.